Modeling Principle

The Mouse A20 Model is a classic syngeneic B‑cell lymphoma model established by inoculating A20 mature B‑cell lymphoma cells derived from BALB/c mice into immunocompetent BALB/c hosts. A20 is a spontaneous B‑cell lymphoma cell line without EBV infection, exhibiting typical biological features of B‑cell neoplasms, with high expression of MHC‑Ⅰ, MHC‑Ⅱ, and B‑cell markers CD19 and CD20. Distinct from human‑derived xenograft models, syngeneic recipients retain intact T‑, B‑ and NK‑cell compartments and preserve physiological tumor immune microenvironment, including tumor‑infiltrating lymphocytes, myeloid‑derived suppressor cells and tumor‑associated macrophages. It represents an SCI gold‑standard model for in‑vivo evaluation of immune checkpoint inhibitors, CAR‑T, tumor vaccines and combination immunotherapies against lymphoma. Two modelling strategies are available: subcutaneous solid tumour for tumour growth monitoring and high‑throughput drug screening; tail‑vein or intraperitoneal dissemination to mimic systemic lymphoma progression with lymph node enlargement, splenic infiltration and abdominal metastasis. This model is widely used to investigate proliferation‑apoptosis and immune‑escape mechanisms as well as immuno‑targeted drug screening for B‑cell lymphoma, and can be directly adopted for NSFC projects, postgraduate research proposals and SCI methodology sections.

Model Validation Criteria

Quantitative Criteria for Tumor Formation and Growth

1.Subcutaneous tumour‑formation criteria: Tumour‑take rate ≥85 % within 2‑3 weeks post‑inoculation; tumour volume＞50 mm³ defines successful engraftment. Vehicle‑control tumours grow progressively without spontaneous regression, reaching average volume 500‑1100 mm³ by week 3.

2.Reproducibility criteria: Intra‑group coefficient of variation (CV) of tumour volume in vehicle control ＜30 %, demonstrating standardized operation and manageable inter‑animal variation.

3.Disseminated / intra‑peritoneal model criteria: Abundant CD19⁺CD45⁺ lymphoma cells are detectable in spleen, lymph‑nodes and peritoneal lavage by flow cytometry; animals develop progressive weight loss and reduced activity with well‑separated survival curves.

4.System‑validity criteria: Positive‑control anti‑PD‑1 treatment yields tumour‑growth suppression or significant survival prolongation (P＜0.05), verifying reliable immunotherapeutic responsiveness of the model system.

Histopathological and Molecular Gold‑Standard Indexes

1.HE‑staining gold standard: Tumour tissue contains abundant atypical B‑lymphocytes with enlarged hyperchromatic nuclei and frequent mitoses together with focal necrosis; disseminated animals show clear lymphoma infiltration in spleen and lymph‑nodes.

2.IHC phenotypic criteria: Tumours are consistently positive for CD19 and CD20 with high Ki‑67 proliferation index, consistent with A20 B‑cell lymphoma identity.

3.Pharmacodynamic‑response criteria: Compared with vehicle, treated groups exhibit reduced Ki‑67 and elevated Cleaved‑Caspase‑3; immunotherapy arms show markedly increased CD8⁺T‑cell infiltration and decreased proportion of immune‑suppressive cells within tumours.

4.Evidence‑closure criteria: In‑vivo immune, pathological and molecular findings are concordant with in‑vitro cellular data to establish a complete evidence chain.

Academic Evidence for Model Validity

Core academic validity evidence for the A20 model: ① BALB/c syngeneic background avoids immune rejection and ensures stable engraftment; ② Recipient mice possess a full immune repertoire enabling simulation of lymphoma tumour‑immune microenvironment; ③ Both subcutaneous solid‑tumour and systemic‑disseminated configurations are available for solid and disseminated lymphoma research scenarios; ④ Reproducible pharmacological responses to immune‑checkpoint inhibitors, chemotherapy and targeted agents; ⑤ Multi‑dimensional readouts including tumour growth, survival, immune‑subset profiling, histopathology and molecular biology. Data generated with this model are widely accepted by hematology‑oncology SCI journals, making it suitable for pre‑clinical translational research on immune escape and novel immunotherapeutics.

Model Advantages

A20 represents the most established syngeneic model for B‑cell lymphoma. Its paramount advantage is the presence of a fully functional host immune system, permitting in‑vivo assessment of immune‑checkpoint inhibitors, tumour vaccines and combination immunotherapies. Modelling procedures are well‑established with high tumour‑take rate and reasonable experimental timeline. Three modelling modalities are supported: subcutaneous solid tumour, tail‑vein dissemination and intra‑peritoneal implantation. Cell culture is straightforward and stable. Data from this model are widely cited in SCI publications with high community acceptance. It fits NSFC grant applications, postgraduate proposals and SCI methodology writing. It complements existing lymphoma xenograft models within the research group, enabling separate evaluation of immunotherapies versus non‑immune‑targeted agents.

Research Applications

The Mouse A20 Model is mainly applied to pre‑clinical immunology research of B‑cell lymphoma, including in‑vivo efficacy evaluation of immune‑checkpoint antibodies, novel immunotherapeutics, tumour vaccines and CAR‑T strategies; efficacy validation for chemotherapeutics and small‑molecule targeted agents as monotherapy or combined with immunotherapy; mechanistic dissection of lymphoma immune escape and tumour‑immune‑microenvironment regulation. Both subcutaneous solid‑lymphoma and disseminated‑lymphoma phenotypes can be investigated. It supports pre‑clinical new‑drug development, national‑ and provincial‑level grant applications, postgraduate proposal and dissertation writing, and SCI methodology construction. It is an irreplaceable gold‑standard syngeneic animal model for B‑cell‑lymphoma immunotherapy research.

Mouse A20 model, A20 B‑cell lymphoma syngeneic model, A20 lymphoma allograft, B‑cell non‑Hodgkin lymphoma, syngeneic tumor model, intact immune microenvironment, lymphoma immunotherapy evaluation, PD‑1/PD‑L1 antibody efficacy, in‑vivo lymphoma model, hematological malignancy pre‑clinical research